Lisata Therapeutics
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
110 Allen Rd Ste 2, Basking Ridge, New J...Phone Number
(908) 842-0100Website
www.lisata.comRevenue
<$5 MillionStock Symbol
LSTAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Explore more
Lisata Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lisata Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Lisata Therapeutics
Click to see if Lisata Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Lisata Therapeutics has new funding data
Earning: See what the market has to say on Lisata Therapeutics recently announced quarterly report
Product Launch: Get notified when Lisata Therapeutics launches new products
Check if Lisata Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Lisata Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Lisata Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Lisata Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Lisata Therapeutics
Compare insights from companies similar to Lisata Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Lisata Therapeutics
<$5M
11-50
Public
<$5M
1980
TI
Tariq ImamSenior Vice President, Business Development, Operations and General Counsel
Company Profile Activity
Activity Insights
Lisata Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lisata Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lisata Therapeutics.
Lisata Therapeutics financials insights
Gather financial insights about Lisata Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Other Financing Round
$2.2M
Lisata Therapeutics Tech Stack
A closer look at the technologies used by Lisata Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Earnings
Earnings
Lisata Therapeutics News & Media
Lisata Therapeutics (LSTA) Buys Marea and Signs $225M Financing. Is the Dilution Worth it?
Lisata Therapeutics, Inc. (NASDAQ:LSTA) announced on September 17 that it completed its acquisition of Marea Therapeutics and signed a definitive agreement for a concurrent private placement expected to raise approximately $225 million gross. Financing completion was expected on September 18, subject to customary closing conditions. Following both transactions, legacy equity holders of Lisata Therapeutics, Inc. […]Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseasesKuva intends to provide new fully funded offer to Lisata Therapeutics
HOUSTON, TX, UNITED STATES, August 21, 2026 /EINPresswire.com/ -- Kuva Labs, Inc. ("Kuva"), a clinical-stage oncology company, today announced its intention to submit a new fully funded offer to the Board of Directors of Lisata Therapeutics, …Lisata Therapeutics moves forward with legal action following Kuva merger termination
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said on Tuesday it has taken decisive action following the termination of its merger agreement with Kuva Labs and its subsidiary Kuva Acquisition Corp, filing suit to protect stockholder interests and moving swiftly to strengthen its financial...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Lisata Therapeutics
Sign Up For FreeTo access detailed company insights
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancr... Read More
